ClinicalTrials.gg
CompletedNCT00163137CORALUpdated Aug 12, 2011

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

A Phase 3 interventional study of lasofoxifene and raloxifene in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 72 sites in United States. Open to female participants aged 48 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-12.

Sponsored by Ligand Pharmaceuticals · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
48 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.

Enrollment
46th of 374
540 · median 73
Started
2003
with 24 others
Phase 3
70 of 481
none open now
Registered
92nd of 481
by date

Among the 481 studies in Osteoporosis with a site in United States, this one is the 46th largest by enrollment of the 374 interventional ones that give a count, is one of 25 that started in 2003, is one of 70 in phase 3, and was the 92nd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 48 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 481 studies in Osteoporosis with a site in United States, or all of them as a file.
02

Study summary

To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
48 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with low bone density (osteopenia) and screening labs, pelvic ultrasound, mammogram without significant findings

Exclusion criteria

Exclusion Criteria:

  • Presence of metabolic bone disease, fractures, blood clots, or recent cancer.
  • Any use of selective estrogen receptor modulators, drugs, or recent use of osteoporosis treatments, certain hormones, or medication for blood clots or seizures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (actual)

Study arms

  • Experimental
    Lasofoxifene 0.25 mg

    lasofoxifene 0.25 mg/day

    Drug: lasofoxifene

  • Active comparator
    raloxifene

    raloxifene 60 mg/day

    Drug: raloxifene

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Spine BMD after 2 years

    Lumbar Spine Bome Mineral Density

    Time frame: 2 years

Secondary outcomes

  1. Hip BMD and LDL-C after 2 years, vaginal pH and Maturation Index after 1 year

    Direct low density lipoprotein cholesterol (LDL-C) at 24 months, vaginal pH at 24 months, vaginal epithelial parabasal cells at 12 months, and total hip BMD at 24 months.

    Time frame: Hip BMD= 24 months, LDL-C= 24 months, vaginal pH= 24 months, vaginal epithelial parabasel cells= 12 months

07

Study locations

72 sites
  • Pfizer Investigational Site
    Albany, California 94706, United States
  • Pfizer Investigational Site
    Berkeley, California 94705, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093-0659, United States
  • Pfizer Investigational Site
    Oakland, California 94609, United States
  • Pfizer Investigational Site
    Oakland, California 94612, United States
  • Pfizer Investigational Site
    Palo Alto, California 94304, United States
  • Pfizer Investigational Site
    Poway, California 92064, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    San Diego, California 92128, United States
  • Pfizer Investigational Site
    Newark, Delaware 19713-2094, United States
  • Pfizer Investigational Site
    Brandon, Florida 33511-5964, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32605, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32607, United States
  • Pfizer Investigational Site
    Key Largo, Florida 33037, United States
  • Pfizer Investigational Site
    Lake Worth, Florida 33461, United States
  • Pfizer Investigational Site
    Leesburg, Florida 34748, United States
  • Pfizer Investigational Site
    Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Miami, Florida 33173, United States
  • Pfizer Investigational Site
    Miami, Florida 33176, United States
  • Pfizer Investigational Site
    Tampa, Florida 33607, United States
  • Pfizer Investigational Site
    Tampa, Florida 33613-3946, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614-7118, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33407, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30308, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50309, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67207, United States
  • Pfizer Investigational Site
    Portland, Maine 04102, United States
  • Pfizer Investigational Site
    Bethesda, Maryland 20817, United States
  • Pfizer Investigational Site
    Gaithersberg, Maryland 20886, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48201, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48236, United States
  • Pfizer Investigational Site
    Southfield, Michigan 48034, United States
  • Pfizer Investigational Site
    Arden Hills, Minnesota 55112, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55415-1226, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Pfizer Investigational Site
    Akron, Ohio 44312-1647, United States
  • Pfizer Investigational Site
    Akron, Ohio 44314, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Portland, Oregon 97213, United States
  • Pfizer Investigational Site
    Portland, Oregon 97220, United States
  • Pfizer Investigational Site
    Monessen, Pennsylvania 15062, United States
  • Pfizer Investigational Site
    Mosessen, Pennsylvania 15062, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Pfizer Investigational Site
    Wyomissing, Pennsylvania 19610-2132, United States
  • Pfizer Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • Pfizer Investigational Site
    Chattanooga, Tennessee 37403, United States
  • Pfizer Investigational Site
    Chattanooga, Tennessee 37412, United States
  • Pfizer Investigational Site
    Cordova, Tennessee 38018, United States
  • Pfizer Investigational Site
    Germantown, Tennessee 38138, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    American Fork, Utah 84003, United States
  • Pfizer Investigational Site
    Pleasant Grove, Utah 84062, United States
  • Pfizer Investigational Site
    Provo, Utah 84064, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84102, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
  • Pfizer Investigational Site
    Chesapeake, Virginia 23320, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23502, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23221, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23225, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23454, United States
  • Pfizer Investigational Site
    Virginia Beach, Virginia 23454, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States
  • Pfizer Investigational Site
    Seattle, Washington 98144, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
May 2003
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Aug 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00163137
First posted
Sep 13, 2005
Start date
May 2003
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Aug 12, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasofoxifene

Start the discussion